Related Experiment Video
Updated: Jun 16, 2026

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
Published on: July 14, 2023
Thiazide therapy in chronic hypoparathyroidism: effects on hypercalciuria and renal function-a systematic review and
Vivek Jha1, Mannuru Venkateswarlu2, Amal Shaharyar1
1Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, Punjab, 160012, India.
Insights
Thiazide diuretics may reduce urinary calcium excretion in chronic hypoparathyroidism, but evidence is limited. Further research is needed to confirm efficacy and long-term renal safety in patients with this condition.
Area of Science:
- Nephrology
- Endocrinology
Background:
- Chronic hypoparathyroidism impairs renal calcium reabsorption, leading to hypercalciuria and increased risk of kidney complications.
- Thiazide diuretics are often used to manage hypercalciuria, but their effectiveness and safety in this context are not well-established.
Purpose of the Study:
- To evaluate the effects of thiazide therapy on urinary calcium excretion and renal outcomes in patients with chronic hypoparathyroidism.
Main Methods:
- A systematic literature search was conducted across major databases (PubMed/MEDLINE, Embase, Scopus, Cochrane CENTRAL).
- Included studies were randomized and observational trials involving adults with chronic hypoparathyroidism treated with thiazides.
- Meta-analysis was performed using a random-effects model to synthesize quantitative data.
Main Results:
- Four studies with 64 participants were included; only two were eligible for quantitative synthesis.
- Meta-analysis showed no significant reduction in urinary calcium excretion (SMD -0.42), with wide confidence intervals indicating substantial imprecision.
- Qualitative data suggested a potential reduction, but pooled estimates were inconclusive due to small sample sizes, heterogeneity, and short follow-up. Renal function remained stable.
Conclusions:
- Current evidence suggests a possible benefit of thiazides in reducing urinary calcium excretion in chronic hypoparathyroidism, but the certainty of this finding is low.
- Inconclusive quantitative results and limited high-quality data necessitate caution.
- Larger, prospective studies are required to definitively establish the efficacy and long-term renal safety of thiazide therapy in this patient population.
Purpose:
Chronic hypoparathyroidism is associated with impaired renal calcium reabsorption, resulting in persistent hypercalciuria and increased risk of nephrolithiasis, nephrocalcinosis, and chronic kidney disease. Thiazide diuretics are commonly used to reduce urinary calcium excretion; however, evidence regarding their efficacy and renal safety remains limited. This study aimed to evaluate the effects of thiazide therapy on hypercalciuria and renal outcomes in patients with chronic hypoparathyroidism.
Methods:
A systematic search of PubMed/MEDLINE, Embase, Scopus, and Cochrane CENTRAL was conducted from inception to January 2026. Randomized and observational studies assessing thiazide therapy in adults with chronic hypoparathyroidism were included. Meta-analysis was performed using a random-effects model, with outcomes expressed as standardized mean differences (SMDs).
Results:
Four studies involving 64 participants were included, comprising three physiological interventional studies and one randomized crossover trial. Two studies (n = 26) were eligible for quantitative synthesis. Meta-analysis showed no statistically significant reduction in urinary calcium excretion (SMD - 0.42; 95% CI - 4.64 to 3.80), with substantial imprecision. Qualitative evidence, including one randomized crossover trial, suggested reductions in urinary calcium excretion with thiazide therapy; however, pooled quantitative estimates remained inconclusive, and overall certainty of evidence was limited by small sample sizes, methodological heterogeneity, and short follow-up durations. Renal function remained stable across studies.
Conclusion:
Current evidence suggests a possible reduction in urinary calcium excretion with thiazide therapy in chronic hypoparathyroidism; however, certainty remains low due to limited heterogeneous data and reliance on predominantly small physiological studies with only one randomized crossover trial. Quantitative pooled estimates were inconclusive, and definitive efficacy or long-term renal benefit remain unproven. Larger, well-designed prospective studies are needed to confirm efficacy and establish long-term renal safety.
Trial Registration Number:
PROSPERO: CRD420261323680.
Related Concept Videos
Antihypertensive Drugs: Thiazide-Class Diuretics
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Antihypertensive Drugs: Potassium-Sparing Diuretics
Urinary Tract Calculi III: Medical Management
Chronic Kidney Disease III: Interprofessional Care
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
